original articleshematologic malignanciesClinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma
hematologic malignancies
Under an Elsevier user license
open archive
Key words
CD5-positive diffuse large B-cell lymphoma
CyclOBEAP
nongerminal center B-cell type
rituximab
Cited by (0)
Copyright © 2010 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.